Published in JAMA on May 19, 2004
Ischemia and reperfusion--from mechanism to translation. Nat Med (2011) 6.64
Pathogenesis of myocardial ischemia-reperfusion injury and rationale for therapy. Am J Cardiol (2010) 2.52
Complement in immune and inflammatory disorders: therapeutic interventions. J Immunol (2013) 1.64
Role of the complement components C5 and C3a in a mouse model of myocardial ischemia and reperfusion injury. Ger Med Sci (2010) 1.05
Mechanisms of complement activation, C4d deposition, and their contribution to the pathogenesis of antibody-mediated rejection. Transplant Rev (Orlando) (2009) 1.03
Mannose-binding lectin-associated serine protease-1 is a significant contributor to coagulation in a murine model of occlusive thrombosis. J Immunol (2011) 1.01
Using next-generation RNA sequencing to examine ischemic changes induced by cold blood cardioplegia on the human left ventricular myocardium transcriptome. Anesthesiology (2015) 0.95
Complement membrane attack is required for endplate damage and clinical disease in passive experimental myasthenia gravis in Lewis rats. Clin Exp Immunol (2006) 0.89
Mesenchymal stromal cells in renal ischemia/reperfusion injury. Front Immunol (2012) 0.87
Implementation of standardized assessment and reporting of myocardial infarction in contemporary randomized controlled trials: a systematic review. Eur Heart J (2013) 0.84
Perioperative elafin for ischaemia-reperfusion injury during coronary artery bypass graft surgery: a randomised-controlled trial. Heart (2015) 0.84
Attenuating the Systemic Inflammatory Response to Adult Cardiopulmonary Bypass: A Critical Review of the Evidence Base. J Extra Corpor Technol (2014) 0.84
Complement activity and pharmacological inhibition in cardiovascular disease. Can J Cardiol (2006) 0.83
Pharmacologic strategies for combating the inflammatory response. J Extra Corpor Technol (2007) 0.82
Mannan-binding lectin in cardiovascular disease. Biomed Res Int (2014) 0.81
Complement C5 and early oxygen kinetics during murine sepsis. Acad Emerg Med (2005) 0.79
Properdin-Mediated C5a Production Enhances Stable Binding of Platelets to Granulocytes in Human Whole Blood. J Immunol (2016) 0.78
Complement activation and cardiac surgery: a novel target for improving outcomes. Anesth Analg (2012) 0.78
Platelets and the complement cascade in atherosclerosis. Front Physiol (2015) 0.77
Anticomplement therapy. Biologics (2008) 0.76
Activation of complement factor B contributes to murine and human myocardial ischemia/reperfusion injury. PLoS One (2017) 0.75
Plasma HDL cholesterol and risk of myocardial infarction: a mendelian randomisation study. Lancet (2012) 12.10
Dabigatran versus warfarin in patients with mechanical heart valves. N Engl J Med (2013) 11.14
Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. N Engl J Med (2003) 10.57
Effect of Sitagliptin on Cardiovascular Outcomes in Type 2 Diabetes. N Engl J Med (2015) 9.70
Guidelines for the diagnosis and treatment of chronic heart failure: executive summary (update 2005): The Task Force for the Diagnosis and Treatment of Chronic Heart Failure of the European Society of Cardiology. Eur Heart J (2005) 7.75
Autologous bone marrow-derived stem-cell transfer in patients with ST-segment elevation myocardial infarction: double-blind, randomised controlled trial. Lancet (2006) 7.33
A validated prediction model for all forms of acute coronary syndrome: estimating the risk of 6-month postdischarge death in an international registry. JAMA (2004) 7.32
The complement inhibitor eculizumab in paroxysmal nocturnal hemoglobinuria. N Engl J Med (2006) 6.90
Sudden death in patients with myocardial infarction and left ventricular dysfunction, heart failure, or both. N Engl J Med (2005) 6.86
Safety of recombinant activated factor VII in randomized clinical trials. N Engl J Med (2010) 6.81
MicroRNAs in the human heart: a clue to fetal gene reprogramming in heart failure. Circulation (2007) 6.41
Fibrinolysis or primary PCI in ST-segment elevation myocardial infarction. N Engl J Med (2013) 6.01
Idarucizumab for Dabigatran Reversal. N Engl J Med (2015) 5.91
Platelet glycoprotein IIb/IIIa inhibitors in acute coronary syndromes: a meta-analysis of all major randomised clinical trials. Lancet (2002) 5.04
Depression as a risk factor for mortality after coronary artery bypass surgery. Lancet (2003) 4.21
Association of myocardial enzyme elevation and survival following coronary artery bypass graft surgery. JAMA (2011) 3.97
Depression as a risk factor for coronary artery disease: evidence, mechanisms, and treatment. Psychosom Med (2004) 3.94
The second Euro Heart Survey on acute coronary syndromes: Characteristics, treatment, and outcome of patients with ACS in Europe and the Mediterranean Basin in 2004. Eur Heart J (2006) 3.62
Effect of tilarginine acetate in patients with acute myocardial infarction and cardiogenic shock: the TRIUMPH randomized controlled trial. JAMA (2007) 3.48
Thrombin-receptor antagonist vorapaxar in acute coronary syndromes. N Engl J Med (2011) 3.20
Prognostic significance of the change in glucose level in the first 24 h after acute myocardial infarction: results from the CARDINAL study. Eur Heart J (2006) 3.14
The safety of moderate hypothermic lower body circulatory arrest with selective cerebral perfusion: a propensity score analysis. J Thorac Cardiovasc Surg (2007) 3.08
Effects of red-cell storage duration on patients undergoing cardiac surgery. N Engl J Med (2015) 3.03
Extracorporeal membrane oxygenation in awake patients as bridge to lung transplantation. Am J Respir Crit Care Med (2012) 2.86
Pharmacogenetics of anesthetic and analgesic agents. Anesthesiology (2005) 2.81
Discovery and development of the complement inhibitor eculizumab for the treatment of paroxysmal nocturnal hemoglobinuria. Nat Biotechnol (2007) 2.81
Effect of eculizumab on hemolysis and transfusion requirements in patients with paroxysmal nocturnal hemoglobinuria. N Engl J Med (2004) 2.80
Cryopreserved human allografts (homografts) for the management of graft infections in the ascending aortic position extending to the arch. Eur J Cardiothorac Surg (2012) 2.70
Symposium on the definition and management of anaphylaxis: summary report. J Allergy Clin Immunol (2005) 2.54
Platelet transfusions during coronary artery bypass graft surgery are associated with serious adverse outcomes. Transfusion (2004) 2.51
Early versus delayed, provisional eptifibatide in acute coronary syndromes. N Engl J Med (2009) 2.49
International differences in evolution of early discharge after acute myocardial infarction. Lancet (2004) 2.47
The association of lowest hematocrit during cardiopulmonary bypass with acute renal injury after coronary artery bypass surgery. Ann Thorac Surg (2003) 2.46
EAE/ASE recommendations for image acquisition and display using three-dimensional echocardiography. J Am Soc Echocardiogr (2012) 2.41
Effect of the complement inhibitor eculizumab on thromboembolism in patients with paroxysmal nocturnal hemoglobinuria. Blood (2007) 2.36
Cardiomyocyte-specific overexpression of nitric oxide synthase 3 improves left ventricular performance and reduces compensatory hypertrophy after myocardial infarction. Circ Res (2004) 2.29
Impact of myocardial haemorrhage on left ventricular function and remodelling in patients with reperfused acute myocardial infarction. Eur Heart J (2009) 2.27
Abciximab as adjunctive therapy to reperfusion in acute ST-segment elevation myocardial infarction: a meta-analysis of randomized trials. JAMA (2005) 2.26
Utility of intraoperative transesophageal echocardiography for diagnosis of pulmonary embolism. Anesth Analg (2004) 2.26
Apolipoprotein E genotype and neurodevelopmental sequelae of infant cardiac surgery. J Thorac Cardiovasc Surg (2003) 2.25
Cardiac output monitoring using indicator-dilution techniques: basics, limits, and perspectives. Anesth Analg (2010) 2.23
Hemodynamic changes after protamine administration: association with mortality after coronary artery bypass surgery. Anesthesiology (2005) 2.22
Dabigatran vs. placebo in patients with acute coronary syndromes on dual antiplatelet therapy: a randomized, double-blind, phase II trial. Eur Heart J (2011) 2.21
ST-segment recovery and outcome after primary percutaneous coronary intervention for ST-elevation myocardial infarction: insights from the Assessment of Pexelizumab in Acute Myocardial Infarction (APEX-AMI) trial. Circulation (2008) 2.19
Periventricular leukomalacia is common after neonatal cardiac surgery. J Thorac Cardiovasc Surg (2004) 2.19
Sex differences in mortality following acute coronary syndromes. JAMA (2009) 2.17
Trends in acute reperfusion therapy for ST-segment elevation myocardial infarction from 1999 to 2006: we are getting better but we have got a long way to go. Eur Heart J (2008) 2.16
Long-term results after aortic valve-sparing operation (David I). Eur J Cardiothorac Surg (2012) 2.16
External validity of clinical trials in acute myocardial infarction. Arch Intern Med (2007) 2.14
Methylene blue: the drug of choice for catecholamine-refractory vasoplegia after cardiopulmonary bypass? J Thorac Cardiovasc Surg (2003) 2.14
Postinfarction ventricular septal defects: towards a new treatment algorithm? Ann Thorac Surg (2009) 2.14
Safety and tolerability of SCH 530348 in patients undergoing non-urgent percutaneous coronary intervention: a randomised, double-blind, placebo-controlled phase II study. Lancet (2009) 2.13
3D echocardiography: a review of the current status and future directions. J Am Soc Echocardiogr (2007) 2.12
Coagulopathy after cardiopulmonary bypass in Jehovah's Witness patients: management of two cases using fractionated components and factor VIIa. Anesth Analg (2007) 2.12
Total aortic arch replacement with a novel four-branched frozen elephant trunk graft: first-in-man results. Eur J Cardiothorac Surg (2012) 2.11
Acute treatment of ST-segment-elevation myocardial infarction: is there a role for the cardiac surgeon? Ann Thorac Surg (2009) 2.11
The failure of orally administered glycoprotein IIb/IIIa inhibitors to prevent recurrent cardiac events. Am J Med (2002) 2.09
The ARCH Projects: design and rationale (IAASSG 001). Eur J Cardiothorac Surg (2013) 2.06
Preoperative haemoglobin concentration and mortality rate after coronary artery bypass surgery. Lancet (2002) 2.06
Intraoperative magnesium administration does not improve neurocognitive function after cardiac surgery. Stroke (2013) 2.05
Long-term cardiac allograft valves after heart transplant are functionally and structurally preserved, in contrast to homografts and bioprostheses. J Heart Valve Dis (2006) 2.04
Improved regional function after autologous bone marrow-derived stem cell transfer in patients with acute myocardial infarction: a randomized, double-blind strain rate imaging study. Eur Heart J (2008) 2.01
Vorapaxar for secondary prevention of thrombotic events for patients with previous myocardial infarction: a prespecified subgroup analysis of the TRA 2°P-TIMI 50 trial. Lancet (2012) 2.00
Sustained ventricular tachycardia and ventricular fibrillation complicating non-ST-segment-elevation acute coronary syndromes. Circulation (2012) 1.99
Safety and efficacy of bioabsorbable magnesium alloy stents in porcine coronary arteries. Catheter Cardiovasc Interv (2006) 1.97
Impact of bleeding severity on clinical outcomes among patients with acute coronary syndromes. Am J Cardiol (2005) 1.96
TGFBR1 and TGFBR2 mutations in patients with features of Marfan syndrome and Loeys-Dietz syndrome. Hum Mutat (2006) 1.93
A variant at chromosome 9p21 is associated with recurrent myocardial infarction and cardiac death after acute coronary syndrome: the GRACE Genetics Study. Eur Heart J (2010) 1.90
Impact of intraoperative transesophageal echocardiography on surgical decisions in 12,566 patients undergoing cardiac surgery. Ann Thorac Surg (2008) 1.89
Natriuretic peptide system gene variants are associated with ventricular dysfunction after coronary artery bypass grafting. Anesthesiology (2009) 1.85
Novel diagnostic test for acute stroke. Stroke (2003) 1.82
A phase III, double-blind, placebo-controlled, multicenter study on the efficacy of recombinant human antithrombin in heparin-resistant patients scheduled to undergo cardiac surgery necessitating cardiopulmonary bypass. Anesthesiology (2005) 1.82
Vascular complications in patients undergoing femoral cannulation for extracorporeal membrane oxygenation support. Ann Thorac Surg (2011) 1.81
Ascending aortic cannulation in acute aortic dissection type A: the Hannover experience. Eur J Cardiothorac Surg (2008) 1.80
From abstract to impact in cardiovascular research: factors predicting publication and citation. Eur Heart J (2012) 1.79
Health-related quality of life and exercise tolerance in recipients of heart transplants and left ventricular assist devices: a prospective, comparative study. J Heart Lung Transplant (2010) 1.78
Does perioperative systolic blood pressure variability predict mortality after cardiac surgery? An exploratory analysis of the ECLIPSE trials. Anesth Analg (2011) 1.77
Acquired von Willebrand syndrome in patients with an axial flow left ventricular assist device. Circ Heart Fail (2010) 1.75
Normothermic perfusion of donor lungs for preservation and assessment with the Organ Care System Lung before bilateral transplantation: a pilot study of 12 patients. Lancet (2012) 1.75
Elephant trunk procedure 27 years after Borst: what remains and what is new? Eur J Cardiothorac Surg (2011) 1.73
Ascending aortic cannulation for Stanford type A acute aortic dissection: another option. J Thorac Cardiovasc Surg (2003) 1.73
A double-blind, placebo-controlled study to assess the mitochondria-targeted antioxidant MitoQ as a disease-modifying therapy in Parkinson's disease. Mov Disord (2010) 1.72
The effect of valsartan, captopril, or both on atherosclerotic events after acute myocardial infarction: an analysis of the Valsartan in Acute Myocardial Infarction Trial (VALIANT). J Am Coll Cardiol (2006) 1.71